It is not
In May, Novo Nordisk agreed a partnership deal with Septerna to jointly discover and develop multiple oral small molecule obesity and cardiometabolic disease drugs
For researchers tracking the latest developments, SeekPeptides provides regular updates on clinical trial outcomes, protocol refinements, and community-sourced observations that complement the official clinical data
Meanwhile, Semaglutide GLP-1 (Ozempic, Wegovy) has shown promising results in terms of weight loss, despite its primary use for treating type 2 diabetes
Never leave GLP-1 in direct sunlight, a hot car, or exposed to room temperature for extended periods, even if you're only running errands
also approved for chronic weight management in adults (refer to current MHRA and NICE Technology Appraisal guidance for the applicable indication and eligibility criteria) [4] [7] Orlistat available on NHS prescription and over the counter Naltrexone/bupropion (Mysimba) available in some settings, though NHS commissioning varies by region [10] NICE Technology Appraisals provide eligibility criteria and commissioning guidance for semaglutide and tirzepatide in weight management